Efficient tobramycin compound conjugate compositions
AssigneeSomerset Therapeutics, LLC
InventorsMandar V. Shah, Veerappan Subramanian, Ilango Subramanian
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
Claims9
A pharmaceutically acceptable composition for treating an infection caused by a bacteria in a mammalian eye comprising an effective amount of an ophthalmologically suitable complex, the complex comprising:
- (a) tobramycin at 0.3-3% w/v and
- (b) polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer (PCL-PVAc-PEG) at 0.3-3% w/v, wherein the PCL-PVAc-PEG forms a stable complex with tobramycin and the PCL-PVAc-PEG detectably promotes the uptake of tobramycin by corneal cells, the retention of tobramycin by corneal cells, or both, as compared to the free (noncomplexed) tobramycin.
Dependencies are inferred from the claim text.